Publications by Dr David Jamieson - ePrints

Browsing publications by Dr David Jamieson.

Newcastle Authors	Title	Year
Dr Shelby Barnett Dr Martin Galler Dr David Jamieson Professor Gareth Veal	Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report	2023
Dr Oladipo Idowu Professor Gareth Veal Dr David Jamieson	Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum	2022
Dr Shelby Barnett Julie Errington Julieann Sludden Dr David Jamieson Professor Gareth Veal et al.	Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population	2021
Swathi Merugu Dr Lindi Chen Elizabeth Gavens Hany Gabra Dr Al Gabriel et al.	Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers	2020
Marian Case Dr Dino Masic Dr David Jamieson Dr Frederik van Delft Professor Andrew Filby et al.	Label-Free Leukemia Monitoring by Computer Vision	2020
Suriyon Uitrakul Dr Claire Hutton Professor Gareth Veal Dr David Jamieson	A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells	2019
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al.	Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase	2018
Dr Jane Margetts Laura Ogle Dr Anthony Chan Dr David Jamieson Dr Catherine Willoughby et al.	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?	2018
Professor Gareth Veal Dr David Jamieson Katja Kuver	Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial	2017
Dr David Jamieson Dr Nicola Sunter Sara Muro Dr Nicola Cresti Julieann Sludden et al.	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide	2017
Professor Edvaldo Ribeiro Rosa Dr Deepali Pal Dr David Jamieson Dr Kenneth Rankin Dr Matthew Benning et al.	Temporary Single Cell Coating for Bioprocessing via a Cationic Polymer	2017
Dr David Jamieson Melanie Griffin Julieann Sludden Dr Yvette Drew Dr Nicola Cresti et al.	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours	2016
Dr Nicola Wyatt Dr Linda Hogarth Dianne Turner Dr Miranda Patterson Dr David Jamieson et al.	Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)	2016
Dr David Jamieson	Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability	2016
Professor Gareth Veal Julieann Sludden Dr David Jamieson Julie Errington Dr Ghada Malik et al.	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma	2016
Dr Nicola Cresti Dr Despina Televantou Dr David Jamieson Dr Mark Verrill Professor Alan Boddy et al.	Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance	2016
Barry Dent Laura Ogle Dr Rachel O'Donnell Dr Ujjal Mallick Professor Nicola Curtin et al.	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers	2016
Laura Ogle Dr James Orr Dr Catherine Willoughby Dr Claire Hutton Professor Stuart McPherson et al.	Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?	2016
Angharad Humphreys Dr Al Gabriel Dr Nicholas Bown Dr Lindi Chen Dr David Jamieson et al.	Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines	2016
Dr Yvette Drew Dr Martin Highley Julieann Sludden Dr James Murray Dr David Jamieson et al.	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer	2016
Professor Alastair Greystoke Dr Linda Hogarth Dr Miranda Patterson Liam Bolt Dianne Turner et al.	The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained	2016
Dr Sheba Macheka Dr David Jamieson Professor Helen Reeves Misti McCain	The isolation and characterisation of circulating tumour cells from patients with hepatocellular carcinoma	2016
Barry Dent Dr Rachel O'Donnell Laura Ogle Padmini Ramesh Nick Hayes et al.	Detection and characterization of circulating tumor cells by imaging flow cytometry	2014
Dr Laura Ogle Dr David Jamieson Dr Rachel O'Donnell Barry Dent Professor Nicola Curtin et al.	Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x	2014
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Dr Celine Cano et al.	Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity	2014
Dr David Jamieson Dr Jo Lee Dr Nicola Cresti Melanie Griffin Julieann Sludden et al.	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil	2014
Christopher Hill Dr David Jamieson Huw Thomas Dr Colin Brown Professor Alan Boddy et al.	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo	2013
Dr Rachel O'Donnell Barry Dent Laura Ogle Professor Nicola Curtin Dr David Jamieson et al.	The Characterisation and Functional Assessment of Epithelial Ovarian Cancer Cells Derived from Ascitic Fluid using Imagestream	2013
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Niu Tan et al.	The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells	2013
Professor Ann Daly Professor Gareth Veal Dr David Jamieson Dr Sally Coulthard	Pharmacogenomics research at Newcastle University	2012
Dr Jane Renwick Shaun Martin Nicola Illingworth Dr David Jamieson Professor Penny Lovat et al.	The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide	2012
Dr Sophie Weatherhead Professor Peter Farr Dr David Jamieson Dr Jennifer Hallinan Dr James Lloyd et al.	Apoptosis of keratinocytes is a key mechanism in UVB-induced clearance of psoriasis	2011
Dr Sophie Weatherhead Professor Peter Farr Dr David Jamieson Dr Jennifer Hallinan Dr James Lloyd et al.	Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation	2011
Dr David Jamieson Professor Alan Boddy	Pharmacogenetics of genes across the doxorubicin pathway	2011
Dr David Jamieson Dr Nicola Cresti Julieann Sludden Melanie Griffin Nahed Hawsawi et al.	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy	2011
Julieann Sludden Melanie Griffin Mike Cole Dr Mark Verrill Dr David Jamieson et al.	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide	2010
Dr Nicola Cresti Dr David Jamieson	The pharmacology of trastuzumab and its use in breast cancer	2010
Dr David Jamieson Dr Nicola Cresti Dr Mark Verrill Professor Alan Boddy	Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma	2009
Dr Sophie Weatherhead Dr David Jamieson Professor Nick Reynolds	Real time imaging of UVB-induced keratinocyte apoptosis, and analysis of factors influencing cell-to-cell variation	2009
Dr Sophie Weatherhead Dr David Jamieson Professor Nick Reynolds	Real-time imaging of ultraviolet B-induced keratinocyte apoptosis to determine duration of apoptosis and effect on tissue turnover	2009
Dr David Jamieson	Mitomycin C	2008
Dr David Jamieson Kerrie Wilson Dr Simon Pridgeon Dr Jane Margetts Professor Richard Edmondson et al.	NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism	2007
Dr David Jamieson Professor Alan Boddy	Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor	2006